Key result
This review examines current stent designs and explores proactive approaches to enhance stent biocompatibility to address the unmet need for platforms with lasting clinical efficacy and safety.
This review highlights the ongoing need for truly biocompatible stent platforms that do not rely solely on drug elution, which can impair endothelial regeneration and increase thrombotic risk.
Answers are grounded in this paper and cite their sources.
Highlights unmet need for durable biocompatible stents; leaves open optimal designs for clinical validation.
Percutaneous coronary intervention has revolutionized the treatment of coronary artery disease. Successive improvements in implantation techniques, stent materials and design, combined with dual antiplatelet therapy have improved stent safety. However, optimal biocompatibility and long-term effectiveness in the absence of pharmaceutical intervention remains elusive. Drug-eluting stents, introduced to combat in-stent restenosis was found to impair endothelial regeneration, increasing thrombotic risk. Innovations in polymer technology and new stent designs have improved, but not solved, these issues. Despite the drawbacks of drug elution it remains a key component of stent platforms, leaving the need for a truly biocompatible platform with lasting clinical efficacy and safety unmet. This review will examine current stent designs and explore proactive approaches to enhance stent biocompatibility.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2015) conducted a review in Coronary artery disease. Bioengineered stents was evaluated. This review examines current stent designs and explores proactive approaches to enhance stent biocompatibility to address the unmet need for platforms with lasting clinical efficacy and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: